| Literature DB >> 34150412 |
Zia U Rehman1, Mohammad Hassan Shah2,3, Muhammad Nauman Shah Afridi4, Hafsa Sardar5, Ahmad Shiraz6.
Abstract
Objective The aim of this study was to determine common microorganisms causing septicemia and their antimicrobial sensitivities in patients admitted to a tertiary care hospital. Methods A cross-sectional study was conducted using clinical criteria to diagnose patients as having septicemia where blood for culture and sensitivity (CS) was sent to the laboratory of a tertiary care hospital, Rehman Medical Institute, (Peshawar), Pakistan, during 2019. All patients diagnosed with septicemia regardless of age and gender were included in the study. The blood CS report was collected after 7-14 days of inoculation. Data were recorded on structured performa and analyzed using SPSS Version 20 (IBM Corp.). Results A total of 176 patients, with a mean age of 2.92±1.32 years, fulfilled the criteria for sepsis with a mean age of 2.92±1.32 years. Among them, 61.9% were male and 38.1% were female. Among common bacterial isolates, Staphylococcus aureus was found in 37.5% of samples followed by skin contaminants (18.2%), methicillin-resistant Staphylococcus aureus (MRSA) (14.8%), and Escherichia coli in (11.4% cases). None of the antibiotics had susceptibility of more than 60%. Susceptibility to piperacillin/tazobactam and ampicillin/sulbactam was found in 21.5% and 14.6% of the samples, respectively, while in cephalosporins, cefoxitin's susceptibility was 28.5%, whereas both ceftriaxone and cephazolin were equally effective in 19.4% cases. Furthermore, 38.9% of the samples were susceptible to ciprofloxacin and 24.3% to levofloxacin. The susceptibilities of amikacin and gentamicin in aminoglycosides were 56.3% and 47.2%, respectively, while that of imipenem and meropenem were 59.7% and 22.9%, respectively. Lastly, clindamycin had an efficacy in 42.4% of samples. Conclusion The susceptibility of bacterial isolates in septicemia to common antibiotics was low, thus risking therapeutic failure in septic patients. Widespread resistance may be due to the excessive use along with over-the-counter availability of antibiotics, which therefore requires regulation as it is an alarming situation.Entities:
Keywords: antibiotic; blood culture; histopathology & microbiology; resistant; sensitivity; susceptibility
Year: 2021 PMID: 34150412 PMCID: PMC8209526 DOI: 10.7759/cureus.15082
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1Common pathogens responsible for causing septicemia
CONS, coagulase-negative Staphylococcal species
Sensitivity and resistance pattern (N=total number of cultures where antibiotic was tested)
| N | Resistant, N (%) | Susceptible, N (%) | |
| Penicillin group | |||
| Ampicillin | 144 | 134 (93.1%) | 10 (6.9%) |
| Amoxicillin/clavulanic acid | 144 | 135 (93.75%) | 9 (6.3%) |
| Amoxicillin | 144 | 138 (95.8%) | 6 (4.2%) |
| Ampicillin/sulbactam | 144 | 123 (85.4%) | 21 (14.6%) |
| Penicillin | 144 | 142 (98.6%) | 02 (1.3%) |
| Piperacillin/tazobactam | 144 | 113 (78.5%) | 31 (21.5%) |
| Cephalosporin group | |||
| Cefaclor | 144 | 127 (88.2%) | 17 (11.8%) |
| Cefazolin | 144 | 116 (80.6%) | 28 (19.4%) |
| Cefoperazone or sulbactam | 144 | 136 (94.4%) | 8 (5.6%) |
| Cefoxitin | 144 | 103 (71.5%) | 41 (28.5%) |
| Cefotaxime | 112 | 106 (94.6%) | 6 (5.4%) |
| Ceftriaxone | 143 | 115 (80.4%) | 28 (19.6%) |
| Cefuroxime | 136 | 111 (81.6%) | 25 (18.4%) |
| Cefixime | 143 | 142 (99.3%) | 1 (0.7%) |
| Cefalexin | 144 | 128 (88.9%) | 16 (11.1%) |
| Cefepime | 143 | 137 (95.8%) | 6 (4.2%) |
| Fluoroquinolone group | |||
| Ciprofloxacin | 144 | 88 (61.1%) | 56 (38.9%) |
| Moxifloxacin | 144 | 130 (90.3%) | 14 (9.7%) |
| Lomefloxacin | 144 | 143 (99.3%) | 1 (0.7%) |
| Levofloxacin | 143 | 108 (75.5%) | 35 (24.5%) |
| Aminoglycoside group | |||
| Tobramycin | 144 | 135 (93.8%) | 9 (6.2%) |
| Fosfomycin | 144 | 143 (99.3%) | 1 (0.7%) |
| Gentamicin | 144 | 76 (52.8%) | 68 (47.2%) |
| Amikacin | 144 | 63 (43.8%) | 81 (56.2%) |
| Monobactam such as aztreonam | 144 | 143 (99.3%) | 1 (0.7%) |
| Carbapenem group | |||
| Invanz ertapenem | 144 | 139 (96.5%) | 5 (3.5%) |
| Imipenem | 144 | 58 (40.3%) | 86 (59.7%) |
| Meropenem | 144 | 111 (77.1%) | 33 (22.9%) |
| Doripenem | 144 | 133 (92.4%) | 11 (7.6%) |
| Macrolide group | |||
| Azithromycin | 144 | 136 (94.4%) | 8 (5.6%) |
| Clarithromycin | 144 | 138 (95.8%) | 6 (4.2%) |
| Clindamycin | 144 | 83 (57.6%) | 61 (42.4%) |
| Erythromycin | 144 | 134 (93.1%) | 10 (6.9%) |
| Other antibiotics | |||
| Chloramphenicol | 144 | 61 (42.4%) | 83 (57.6%) |
| Co-trimoxazole | 144 | 94 (65.3%) | 50 (34.7%) |
| Doxycycline | 144 | 68 (47.2%) | 76 (52.8%) |
| Vancomycin | 144 | 60 (41.7%) | 84 (58.3%) |
| Minocycline | 144 | 76 (52.8%) | 68 (47.2%) |
| Rifampicin | 144 | 99 (68.8%) | 45 (31.2%) |
| Novobiocin | 144 | 143 (99.3%) | 1 (0.7%) |
| Colistin | 144 | 140 (97.2%) | 4 (2.8%) |
| Nalidixic acid | 144 | 144 (100%) | 0.0 (0%) |
| Tigecycline | 144 | 143 (99.3%) | 1 (0.7%) |
| Nitrofurantoin | 144 | 143 (99.3%) | 1 (0.7%) |
| Teicoplanin | 144 | 141 (97.9%) | 3 (2.1%) |